Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Front Oncol · 2026 · PMC13322814 · PMID 42394707

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

The data suggest a clinically relevant trend favoring T-DM1, which likely failed to reach statistical significance due to insufficient statistical power resulting from the limited sample size.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.